Clinical evaluation of Fleroxacin in the oral infections

Abstract

Fleroxacin (FLRX), an oral antimicrobial agent of a new quinolone derivative, was evaluated clinically and bacteriologically in 90 cases with oral infections such as periodontitis, pericoronitis and osteitis of the jaw.
A dose level of 200.300mg once daily was used, and the following results were obtained.
1) The clinical efficacy rats was 90.0 % according to the numerical rating on the 3rd day of treatment, and 88.9 % by the judgement of the doctors in charge.
2) Side effects were obtained in four cases (4.2 %), however, the symptoms were not serious.
Abnormal changes of laboratory findings were noted in three cases, but these were not serious.
3) A total of 101 strains were isolated from the pus of abscesses, of which 53 strains (52.5 %) were anaerobes, indicating the important role of anaerobes in oral infections.